Harvard Apparatus Regenerative Technology Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

	June 30,	December 31,
	2024	2023
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$139	$432
Accounts receivable	—	4
Inventory	60	50
Prepaid research and development	343	210
Prepaid expenses and other current assets	114	87
Total current assets	656	783
Property, plant and equipment, net	14	25
Right-of-use assets, net	68	48
Deferred financing costs	—	544
Long-term prepaid contracts	992	1,214
Total assets	$1,730	$2,614
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$752	$445
Accrued and other current liabilities	700	475
Convertible debt – related party	500	—
Operating lease liability	40	48
Total current liabilities	1,992	968
Operating lease liability, net of current portion	28	—
Total liabilities	2,020	1,411
Commitments and contingencies (Note 7)	-
Stockholders’ (deficit) equity:
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 14,315,091 and 13,947,324 issued and outstanding at June 30, 2024 and December 31, 2023, respectively	143	139
Additional paid-in capital	96,073	93,463
Accumulated deficit	(96,484)	(91,956)
Accumulated other comprehensive loss	(22)	—
Total stockholders’ (deficit) equity	(290)	1,646
Total liabilities and stockholders’ (deficit) equity	$1,730	$2,614

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.